Inhibrx Biosciences, Inc. (INBX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $109.37: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate... Read more
Sell if holding. Engine safety override at $109.37: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Inhibrx Biosciences, Inc.
Latest news
- Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate — benzinga May 14, 2026 negative
- Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study — benzinga May 11, 2026 positive
- Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC — benzinga May 11, 2026 positive
- 12 Health Care Stocks Moving In Friday's After-Market Session — benzinga May 8, 2026 neutral
- Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer — benzinga May 8, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $109.37: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10 and A.R:R 7.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 25%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $101.98. Score 4.2/10, moderate confidence.
Take-profit target: $235.88 (+115.1% upside). Prior stop was $101.98. Stop-loss: $101.98.
Quality below floor (1.8 < 4.0).
Inhibrx Biosciences, Inc. trades at a P/E of N/A (forward -37.9). TrendMatrix value score: 5.0/10. Verdict: Sell.
9 analysts cover INBX with a consensus score of 4.1/5. Average price target: $278.
What does Inhibrx Biosciences, Inc. do?Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic...
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.